Payment overview · 2025
General Payments
$294.42
16 reported records · 10 companies
Healthcare provider profile · identity verified
Michael Greggory Barden, M.D,
Allopathic & Osteopathic Physicians|Family Medicine · SEARCY, AR · NPI 1427018043
Verified facts
What the public records show
CMS Open Payments records show Michael Greggory Barden, M.D, received $294.42 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.90 | 20.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.97 | 15.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.40 | 15.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.04 | 10.9% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.63 | 8.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.01 | 7.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.63 | 6.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.48 | 5.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.80 | 5.7% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $12.56 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $294.42 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.90 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.90 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.97 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.40 | 3 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 96 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 208 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
208 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 641 | 135 |
| Atorvastatin Calcium | Atorvastatin Calcium | 625 | 158 |
| Omeprazole | Omeprazole | 611 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 137 |
| Gabapentin | Gabapentin | 511 | 105 |
| Lisinopril | Lisinopril | 438 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 431 | 108 |
| Metformin Hcl | Metformin Hcl | 407 | 99 |
| Losartan Potassium | Losartan Potassium | 367 | 101 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 354 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 314 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 62 |
| Potassium Chloride | Potassium Chloride | 275 | 73 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 247 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 243 | 76 |
| Trazodone Hcl | Trazodone Hcl | 237 | 46 |
| Meloxicam | Meloxicam | 232 | 73 |
| Ozempic | Semaglutide | 208 | 39 |
| Carvedilol | Carvedilol | 189 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 41 |
| Famotidine | Famotidine | 178 | 50 |
| Furosemide | Furosemide | 169 | 49 |
| Simvastatin | Simvastatin | 167 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 167 | 46 |
| Metformin Hcl Er | Metformin Hcl | 161 | 38 |
| Tramadol Hcl | Tramadol Hcl | 158 | 36 |
| Cefdinir | Cefdinir | 155 | 109 |
| Alprazolam | Alprazolam | 149 | 21 |
| Finasteride | Finasteride | 146 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 34 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 142 | 116 |
| Eliquis | Apixaban | 138 | 20 |
| Sertraline Hcl | Sertraline Hcl | 129 | 29 |
| Allopurinol | Allopurinol | 128 | 28 |
| Montelukast Sodium | Montelukast Sodium | 128 | 32 |
| Prednisone | Prednisone | 124 | 67 |
| Atenolol | Atenolol | 123 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 114 | 23 |
| Buspirone Hcl | Buspirone Hcl | 112 | 21 |
| Celecoxib | Celecoxib | 109 | 25 |
| Donepezil Hcl | Donepezil Hcl | 102 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 33 |
| Mirtazapine | Mirtazapine | 100 | 24 |
| Clonazepam | Clonazepam | 99 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 98 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 20 |
| Jardiance | Empagliflozin | 96 | 20 |
| Enalapril Maleate | Enalapril Maleate | 95 | 22 |
| Xarelto | Rivaroxaban | 95 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 21 |
| Spironolactone | Spironolactone | 91 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 31 |
| Synthroid | Levothyroxine Sodium | 85 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 82 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 79 | 55 |
| Glipizide | Glipizide | 78 | 21 |
| Valsartan | Valsartan | 78 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 14 |
| Naproxen | Naproxen | 77 | 18 |
| Fluconazole | Fluconazole | 76 | 42 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | 15 |
| Warfarin Sodium | Warfarin Sodium | 69 | 12 |
| Amoxicillin | Amoxicillin | 68 | 64 |
| Ondansetron Odt | Ondansetron | 66 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 12 |
| Chlorthalidone | Chlorthalidone | 63 | 16 |
| Alendronate Sodium | Alendronate Sodium | 62 | 20 |
| Estradiol | Estradiol | 62 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 61 | 11 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 58 | suppressed |
| Glimepiride | Glimepiride | 57 | 13 |
| Pregabalin | Pregabalin | 56 | 14 |
| Propranolol Hcl | Propranolol Hcl | 56 | 14 |
| Cephalexin | Cephalexin | 55 | 35 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 39 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 16 |
| Azithromycin | Azithromycin | 52 | 38 |
| Lactulose | Lactulose | 52 | 29 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Sucralfate | Sucralfate | 52 | 12 |
| Valacyclovir | Valacyclovir Hcl | 52 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 50 | suppressed |
| Irbesartan | Irbesartan | 50 | 12 |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 13 |
| Azelastine Hcl | Azelastine Hcl | 41 | 13 |
| Temazepam | Temazepam | 41 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 28 |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Nystatin | Nystatin | 32 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Lexapro | Escitalopram Oxalate | 12 | suppressed |
| Mercaptopurine | Mercaptopurine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $294.42 · 16 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, INCEPTIV, JARDIANCE, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error